A HIGH-tech Oxfordshire company has set up a new joint venture with a US partner injecting £20m to commercialise its ‘digital plaster’, Sensium.
The Sensium ‘plaster’ is a body monitor developed by Toumaz, of Culham Science Centre, to allow hospital staff to measure people’s vital signs, including temperature, heart rate and respiration.
It has been approved by US drug regulators and the new venture will have its headquarters in San Diego.
Toumaz believes it could be used in tele-care, chronic disease monitoring, community care settings and the homes of people who need continuous or extended monitoring.
Dr Patrick Soon-Shiong, of Toumaz’s US partner, California Capital Equity, said: “Wireless technology is the key to bringing quality healthcare to everybody, wherever they may be, in real time.
“Toumaz’s ultra-low power technology is going to be a vital element in this, and our joint venture opens up exciting prospects."
Toumaz chief executive Professor Chris Toumazou, said: “We are very excited to be working closely with Dr Patrick Soon-Shiong.
“We share his vision of building a better healthcare system by enabling remote patient monitoring.”
California Capital Equity will own 80 per cent of the equity, with Toumaz owning the remainder. Toumaz will also receive product and royalty revenues from any sales.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here